arginine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1549	74-79-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: l-arginine L-Arg arginine arginine hydrochloride arginine HCl	An essential amino acid that is physiologically active in the L-form. Molecular weight: 174.20 Formula: C6H14N4O2 CLOGP: -3.04 LIPINSKI: 0 HAC: 6 HDO: 5 TPSA: 125.22 ALOGS: -1.88 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

l-arginine
L-Arg
arginine
arginine hydrochloride
arginine HCl

An essential amino acid that is physiologically active in the L-form.

Molecular weight: 174.20
Formula: C6H14N4O2
CLOGP: -3.04
LIPINSKI: 0
HAC: 6
HDO: 5
TPSA: 125.22
ALOGS: -1.88
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	68 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.32 L/kg	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Showing 1 to 2 of 2 entries

Previous1Next

Approvals:

Show entries

Search:

Date	Agency	Company
Feb. 28, 1973	FDA	PHARMACIA AND UPJOHN
July 25, 2019	EMA	Advanced Accelerator Applications
June 23, 2021	PMDA	FUJIFILM TOYAMA CHEMICAL Co., Ltd.

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperammonaemic crisis	58.76	24.94	7	945	32	63488038
Foetal growth restriction	58.52	24.94	15	937	7538	63480532
Infantile apnoea	42.03	24.94	8	944	1025	63487045
Selective eating disorder	36.47	24.94	8	944	2064	63486006
Hyperammonaemia	33.80	24.94	9	943	5223	63482847
Cerebral haemorrhage	30.96	24.94	13	939	30716	63457354
Ammonia increased	30.03	24.94	8	944	4648	63483422
Right ventricular failure	26.89	24.94	10	942	17178	63470892
Device related sepsis	26.24	24.94	7	945	4087	63483983

Showing 1 to 9 of 9 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperammonaemic crisis	84.48	25.13	11	1032	52	34955836
Haematuria	77.43	25.13	35	1008	50031	34905857
Blindness cortical	57.55	25.13	10	1033	383	34955505

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperammonaemic crisis	108.45	21.65	14	1653	93	79742628
Haematuria	72.12	21.65	33	1634	68803	79673918
Blindness cortical	51.89	21.65	10	1657	977	79741744
Hyperammonaemia	39.63	21.65	13	1654	11080	79731641
Ammonia increased	35.76	21.65	11	1656	7624	79735097
Blood osmolarity decreased	26.28	21.65	6	1661	1325	79741396
Status epilepticus	26.15	21.65	12	1655	25029	79717692

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	B05XB01	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Amino acids
ATC	V03AF11	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment
CHEBI has role	CHEBI:27027	trace elements
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:59163	biological marker
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:78675	fundamental metabolites
CHEBI has role	CHEBI:75772	S. cerevisiae metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Showing 1 to 10 of 10 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Renal radiation exposure from Lutetium (177Lu) oxodotreotide	indication	218190002
Diagnostic Test for Growth Hormone Secretion	indication
Renal tubular acidosis	contraindication	1776003	DOID:14219
Classical phenylketonuria	contraindication	7573000
Poisoning by digitalis glycoside	contraindication	12876009
Hyperkalemia	contraindication	14140009
Constipation	contraindication	14760008	DOID:2089
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
End stage renal disease	contraindication	46177005	DOID:784

Showing 1 to 10 of 23 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.97	acidic
pKa2	11.72	Basic
pKa3	8.95	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Nitric oxide synthase, inducible	Enzyme	P35228	NOS2_HUMAN		Kd	5.15		CHEMBL
G-protein coupled receptor family C group 6 member A	GPCR	Q5T6X5	GPC6A_HUMAN	AGONIST	EC50	4.40		IUPHAR

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
ARG	PDB_CHEM_ID
000926	NDDF
005095	NDDF
1091	RXNORM
1119-34-2	SECONDARY_CAS_RN
14778	MMSL
1711	INN_ID
206	MMSL
40033	MMSL
4018668	VUID

Showing 1 to 10 of 30 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	690 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	690 mg	INTRAVENOUS	NDA	21 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next